155 related articles for article (PubMed ID: 35151549)
1. Gadoxetic Acid-Enhanced MRI Features for Predicting Treatment Outcomes of Early Hepatocellular Carcinoma (< 3 cm) After Transarterial Chemoembolization.
Lee BC; Jeong YY; Heo SH; Kim HO; Park C; Shin SS; Cho SB; Koh YS
Acad Radiol; 2022 Sep; 29(9):e178-e188. PubMed ID: 35151549
[TBL] [Abstract][Full Text] [Related]
2. Hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with HCC: prognostic features before resection, ablation, or TACE.
Bae JS; Kim JH; Lee DH; Kim JH; Han JK
Eur Radiol; 2021 Jun; 31(6):3627-3637. PubMed ID: 33211146
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Preoperative MRI-derived 3D Quantitative Tumor Arterial Burden in Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization.
Peng G; Huang XY; Wang YN; Cao XJ; Zhou X
Radiol Imaging Cancer; 2024 May; 6(3):e230167. PubMed ID: 38607280
[TBL] [Abstract][Full Text] [Related]
4. Prediction of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma using imaging features of gadoxetic acid-enhanced magnetic resonance imaging.
Byun J; Kim SY; Kim JH; Kim MJ; Yoo C; Shim JH; Lee SS
Acta Radiol; 2021 Dec; 62(12):1548-1558. PubMed ID: 33197329
[TBL] [Abstract][Full Text] [Related]
5. Thermal Ablation Versus Stereotactic Body Radiotherapy After Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.
Nabavizadeh N; Jahangiri Y; Rahmani R; Tomozawa Y; Geeratikun Y; Chen Y; Hung A; Degnin C; Farsad K
AJR Am J Roentgenol; 2021 Sep; 217(3):691-698. PubMed ID: 32997517
[No Abstract] [Full Text] [Related]
6. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma.
Lee JS; Chon YE; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kang W; Choi MS; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Kim HY; Kim TH; Yoo K; Ha Y; Kim MN; Lee JH; Hwang SG; Kim SS; Cho HJ; Cheong JY; Cho SW; Park SH; Heo NY; Hong YM; Yoon KT; Cho M; Park JG; Kang MK; Park SY; Kweon YO; Tak WY; Jang SY; Sinn DH; Kim SU;
Yonsei Med J; 2021 Jan; 62(1):12-20. PubMed ID: 33381930
[TBL] [Abstract][Full Text] [Related]
7. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.
Tian X; Dai Y; Wang DQ; Zhang L; Sui CG; Meng FD; Jiang SY; Liu YP; Jiang YH
Drug Des Devel Ther; 2015; 9():4431-40. PubMed ID: 26309396
[TBL] [Abstract][Full Text] [Related]
8. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
9. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
10. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Survival Factors of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Rohan T; Uher M; Matkulčík P; Zavadil J; Ostřížková L; Kiss I; Andrašina T; Válek V
Klin Onkol; 2020; 33(3):214-219. PubMed ID: 32683878
[TBL] [Abstract][Full Text] [Related]
12. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
[TBL] [Abstract][Full Text] [Related]
13. Liver MRI and clinical findings to predict response after drug eluting bead transarterial chemoembolization in hepatocellular carcinoma.
Lee JY; Lee BC; Kim HO; Heo SH; Shin SS; Jeong YY
Sci Rep; 2021 Dec; 11(1):24076. PubMed ID: 34911966
[TBL] [Abstract][Full Text] [Related]
14. Radiomics analysis of pretreatment MRI in predicting tumor response and outcome in hepatocellular carcinoma with transarterial chemoembolization: a two-center collaborative study.
Liu QP; Yang KL; Xu X; Liu XS; Qu JR; Zhang YD
Abdom Radiol (NY); 2022 Feb; 47(2):651-663. PubMed ID: 34918174
[TBL] [Abstract][Full Text] [Related]
15. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI.
Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
AJR Am J Roentgenol; 2013 Sep; 201(3):675-83. PubMed ID: 23971463
[TBL] [Abstract][Full Text] [Related]
16. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
17. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M
Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization.
Baek MY; Yoo JJ; Jeong SW; Jang JY; Kim YK; Jeong SO; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim YJ; Park SY
Korean J Intern Med; 2019 Nov; 34(6):1223-1232. PubMed ID: 30360019
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
Wen P; Chen SD; Wang JR; Zeng YH
Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
[TBL] [Abstract][Full Text] [Related]
20. Survival benefit of radiofrequency ablation for solitary (3-5 cm) hepatocellular carcinoma: An analysis for nationwide cancer registry.
Lee SH; Jin YJ; Lee JW
Medicine (Baltimore); 2017 Nov; 96(44):e8486. PubMed ID: 29095307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
